- Home
- CLDX vs PHVS Comparison
CLDX vs PHVS Comparison
Compare CLDX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- PHVS
- Stock Information
- Founded
- CLDX N/A
- PHVS 2015
- Country
- CLDX United States
- PHVS Switzerland
- Employees
- CLDX N/A
- PHVS N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- PHVS Health Care
- Exchange
- CLDX Nasdaq
- PHVS Nasdaq
- Market Cap
- CLDX 1.6B
- PHVS 1.6B
- IPO Year
- CLDX 2008
- PHVS 2021
- Fundamental
- Price
- CLDX $26.22
- PHVS $22.31
- Analyst Decision
- CLDX Strong Buy
- PHVS Buy
- Analyst Count
- CLDX 8
- PHVS 4
- Target Price
- CLDX $46.13
- PHVS $33.00
- AVG Volume (30 Days)
- CLDX 1.1M
- PHVS 222.4K
- Earning Date
- CLDX 11-05-2025
- PHVS 11-12-2025
- Dividend Yield
- CLDX N/A
- PHVS N/A
- EPS Growth
- CLDX N/A
- PHVS N/A
- EPS
- CLDX N/A
- PHVS N/A
- Revenue
- CLDX $5,790,000.00
- PHVS N/A
- Revenue This Year
- CLDX N/A
- PHVS N/A
- Revenue Next Year
- CLDX N/A
- PHVS N/A
- P/E Ratio
- CLDX N/A
- PHVS N/A
- Revenue Growth
- CLDX N/A
- PHVS N/A
- 52 Week Low
- CLDX $14.40
- PHVS $11.51
- 52 Week High
- CLDX $31.66
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- CLDX 60.30
- PHVS 41.09
- Support Level
- CLDX $24.49
- PHVS $22.71
- Resistance Level
- CLDX $26.90
- PHVS $24.01
- Average True Range (ATR)
- CLDX 1.00
- PHVS 1.25
- MACD
- CLDX 0.07
- PHVS -0.31
- Stochastic Oscillator
- CLDX 79.27
- PHVS 3.28
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.